First fluconazole-resistant Candida auris isolated from fungal otitis in Iran

Document Type : Case report

Authors

1 Department of Medical Mycology and Parasitology, School of Medicine, Babol University of Medical Sciences, Babol, Iran

2 Department of Ear, Nose, and Throat, Faculty of Medicine, Roohani Hospital, Babol University of Medical Sciences, Babol, Iran

3 Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

4 Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

5 Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran

10.18502/cmm.7.1.6243

Abstract

Background and Purpose: Candida auris, as a new characterized pathogenic yeast,has attracted remarkable attention in the recent decade due to its rapid global emergence and multidrug resistance traits. This unique species is able to cause nosocomial outbreaks and tolerate adverse conditions; however, it has been mostly misidentified by conventional methods.
Case report: This report aimed to describe the first fluconazole-resistant case of C.auris otitis in an immunocompetent patient in Iran. The isolate showed minimum inhibitory concentration of ≥ 32 μg/ml for fluconazole; however, the patient was treated with topical clotrimazole and miconazole with no recurrence.
Conclusion: This was the second strain of C. auris isolated from otitis in Iran which was fluconazole-resistant, unlike the first Iranian isolate.

Keywords

References

1. Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida
auris: Epidemiology, biology, antifungal resistance, and
virulence. Plos Pathogens. 2020 Oct 22;16 (10):e1008921.
2. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM,
Borman A, Manuel R, Brown CS. Candida auris: a review of
the literature. Clinical microbiology reviews. 2018 Jan 1;31(1).
3. Alfouzan W, Dhar R, Albarrag A, Al-Abdely H. The emerging
pathogen Candida auris: A focus on the Middle-Eastern
countries. Journal of infection and public health. 2019 Jul
1;12(4):451-9.
4. Ruiz GB, Lorenz A. What do we know about the biology of the
emerging fungal pathogen of humans Candida auris?: Running
Title: The basic biology of C. auris. Microbiological Research.
2020 Oct 9:126621.
5. Abastabar M, Haghani I, Ahangarkani F, Rezai MS, Taghizadeh
Armaki M, Roodgari S, Kiakojuri K, Al‐Hatmi AM, Meis JF,
Badali H. Candida auris otomycosis in Iran and review of recent
literature. Mycoses. 2019 Feb;62(2):101-5.
6. Didehdar M, Shokohi T, Khansarinejad B, Sefidgar SA,
Abastabar M, Haghani I, Amirrajab N, Mondanizadeh M.
Characterization of clinically important dermatophytes in North
of Iran using PCR-RFLP on ITS region. Journal de mycologie
medicale. 2016 Dec 1;26(4):345-50.
7. Kordalewska M, Zhao Y, Lockhart SR, Chowdhary A, Berrio I,
Perlin DS. Rapid and accurate molecular identification of the
emerging multidrug-resistant pathogen Candida auris. Journal of
clinical microbiology. 2017 Aug 1;55(8):2445-52.
8. Clinical and Laboratory Standards Institute. 2018. Reference
Method for Broth Dilution Antifungal Susceptibility Testing of
Yeasts: Fourth edition M27-S4. CLSI, Wayne, PA, USA.
9. Chakrabarti, A.; Sood, P.; Rudramurthy, S.M.; Chen, S.; Kaur,
H.; Capoor, M.; Chhina, D.; Rao, R.; Eshwara, V.K.; Xess, I.; et
al. Incidence, characteristics and outcome of ICU-acquired
candidemia in India. Intensive Care Med. 2015, 41, 285–295.
10. Milena Kordalewska, David S. Perlin. Identification of Drug
Resistant Candida auris. Frontiers in Microbiology. 2019;
10:1918.
11. Chowdhary, A., Sharma, C., and Meis, J. F.. Candida auris: a
rapidly emerging cause of hospital-acquired multidrug-resistant
fungal infections globally. PLoS Pathog. 2017; 13:e1006290.
12. Hyde, K.D.; Al-Hatmi, A.M.S.; Andersen, B.; Boekhout, T.;
Buzina, W.; Dawson, T.L.; Eastwood, D.C.; Jones, E.B.G.; de
Hoog, S.; Kang, Y.; et al. The world’s ten most feared fungi.
Fungal Diversity 2018.
13. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K,
Yamaguchi H. Candida auris sp. nov., a novel ascomycetous
yeast isolated from the external ear canal of an inpatient in a
Japanese hospital. Microbiology and immunology. 2009
Jan;53(1):41-4.
14. Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, Lee JS,
Jung SI, Park KH, Kee SJ, Kim SH. Candida haemulonii and
closely related species at 5 university hospitals in Korea:
identification, antifungal susceptibility, and clinical features.
Clinical Infectious Diseases. 2009 Mar 15;48(6):e57-61.
15. Pekard-Amenitsch S, Schriebl A, Posawetz W, Willinger B,
Kölli B, Buzina W. Isolation of Candida auris from ear of
otherwise healthy patient, Austria, 2018. Emerging infectious
diseases. 2018 Aug;24(8):1596.
16. Riat A, Neofytos D, Coste A, Harbarth S, Bizzini A,
Grandbastien B, Pugin J, Lamoth F. First case of Candida auris
in Switzerland: discussion about preventive strategies. Swiss
medical weekly. 2018;148.
17. Yang A, Carlton DA, Hamula C, Patel G, Iloreta AM. First
prospectively identified case of Candida auris in the United
States. Otolaryngology Case Reports. 2017 Nov 1;5:6-7.
18. Schwartz IS, Hammond GW. Outbreak Detection: First reported
case of multidrug-resistant Candida auris in Canada. Canada
Communicable Disease Report. 2017 Jul 6;43(7-8):150.
19. Sayeed MA, Farooqi J, Jabeen K, Awan S, Mahmood SF.
Clinical spectrum and factors impacting outcome of Candida
auris: a single center study from Pakistan. BMC infectious
diseases. 2019 Dec 1;19(1):384.
20. Iguchi S, Mizushima R, Kamada K, Itakura Y, Yoshida A,
Uzawa Y, Arai Y, Takaoka M, Sato S, Goto A, Karasawa T. The
second Candida auris isolate from aural discharge in Japan.
Japanese Journal of Infectious Diseases. 2018:JJID-2017.
21. Alfouzan W, Dhar R, Albarrag A, Al-Abdely H. The emerging
pathogen Candida auris: A focus on the Middle-Eastern
countries. Journal of infection and public health. 2019 Jul
1;12(4):451-9.
22. Chowdhary A, Prakash A, Sharma C, et al. A multicentre study
of antifungal susceptibility patterns among 350 Candida auris
isolates (2009-17) in India: role of the ERG11 and FKS1 genes
in azole and echinocandin resistance. J Antimicrob Chemother.
2018;73:891‐899.
23. Pekard-Amenitsch S, Schriebl A, Posawetz W, Willinger B,
Kölli B, Buzina W. Isolation of Candida auris from ear of
otherwise healthy patient, Austria, 2018. Emerging infectious
diseases. 2018 Aug;24(8):1596.
24. Lepak AJ, Zhao M, Berkow EL, Lockhart SR, Andes DR. 2017.
Pharmacodynamic optimization for treatment of invasive Candida
auris infection. Antimicrob Agents Chemother 61:e00791-17.
25. Chow NA, de Groot T, Badali H, Abastabar M, Chiller TM,
Meis JF. Potential fifth clade of Candida auris, Iran, 2018.
Emerging infectious diseases. 2019 Sep;25(9):1780. 
Current Medical Mycology
Volume 7, Issue 1
March 2021
Pages 51-54

Files

History

  • Receive Date: 05 December 2020
  • Revise Date: 10 January 2021
  • Accept Date: 18 January 2021
  • First Publish Date: 01 March 2021

Share

How to cite

Statistics